AssetMark’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-123,492
Closed -$3.88M – 3792
2026
Q2
$3.88M Buy
123,492
+21,056
+21% +$621K 0.01% 804
2026
Q1
$2.54M Buy
102,436
+16,299
+19% +$388K 0.01% 827
2025
Q4
$2.01M Sell
86,137
-3,172
-4% -$70.7K ﹤0.01% 852
2025
Q3
$1.76M Buy
89,309
+12,669
+17% +$261K ﹤0.01% 851
2025
Q2
$1.66M Sell
76,640
-6,596
-8% -$156K ﹤0.01% 807
2025
Q1
$2.02M Buy
83,236
+12,434
+18% +$280K 0.01% 721
2024
Q4
$1.48M Sell
70,802
-1,443
-2% -$31K ﹤0.01% 775
2024
Q3
$1.44M Buy
72,245
+1,704
+2% +$31.6K ﹤0.01% 718
2024
Q2
$1.09M Buy
70,541
+1,866
+3% +$29K ﹤0.01% 743
2024
Q1
$1.09M Buy
68,675
+3,997
+6% +$60.2K ﹤0.01% 713
2023
Q4
$1.09M Buy
64,678
+2,505
+4% +$34.2K ﹤0.01% 660
2023
Q3
$727K Buy
62,173
+6,218
+11% +$83.2K ﹤0.01% 685
2023
Q2
$752K Sell
55,955
-2,093
-4% -$30.1K ﹤0.01% 654
2023
Q1
$962K Buy
58,048
+566
+1% +$9.34K ﹤0.01% 606
2022
Q4
$1.07M Sell
57,482
-1,650
-3% -$25.4K ﹤0.01% 555
2022
Q3
$759K Buy
+59,132
New +$701K ﹤0.01% 578

Other funds holding CPRX

AssetMark's CPRX Position: Q3 2026 in Review

AssetMark sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 123,492 shares — an estimated $3.88M sold.

AssetMark first reported a position in CPRX in Q3 2022 and held it in 16 quarters. The position peaked at $3.88M in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

  • AssetMark reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • AssetMark sold 123,492 Catalyst Pharmaceutical shares in Q3 2026, an estimated $3.88M.
  • AssetMark first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 16 quarters.
  • AssetMark's Catalyst Pharmaceutical position peaked at $3.88M in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.